Tysabri sBLA Includes Label Revisions, Risk Management Plan

Drug Industry Daily
KEYWORDS FDA
A A

Biogen Idec and Elan’s plan to revive its withdrawn multiple sclerosis (MS) drug Tysabri includes revisions to the product’s label, as well as the establishment of a risk management plan for the drug.

To View This Article:

Login

Subscribe To Drug Industry Daily